MedPath

The evaluation of efficacy for remission maintenance with immunomodulator following remission induction with tacrolimus in patients with moderate to severe active refractory ulcerative colitis.:mucosal healing for prognosis

Not Applicable
Conditions
The patients with moderate to severe active refractory ulcerative colitis
Registration Number
JPRN-UMIN000004201
Lead Sponsor
Osaka City University, Graduate School of Medicine,Department of Gastroenterology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1)The treatment with immunomodulator or anti-TNF alpha agents within 12 weeks before administration of tacrolimus 2)The treatment with cytapheresis within 12 weeks before administration of tacrolimus 3)The patients who are not suitable for treatment of immunomodulator 4)The patients after colectomy 5)the patients with renal disorder

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath